多发性硬化步态障碍患者长期使用法普鲁啶的疗效监测
结果显示法普鲁啶长期治疗耐受性良好且疗效持续,部分患者药物反应性随时间变化,强调定期重新评估疗效的重要性。
要点
- 法普鲁啶长期治疗可持续改善步速、耐力和自感步行功能。
- 部分患者药物反应性随时间变化,需定期重新评估疗效。
- 初始反应不佳者长期治疗后反应性可能增强。
核心结论
- 法普鲁啶长期治疗对步态受损的多发性硬化患者安全有效,可改善步行功能。
- 开放标签与双盲阶段结果相似,表明所用步行测试客观可靠。
- 相当比例患者药物反应性随时间变化,强调定期重新评估的必要性。
研究设计与样本
- 采用开放标签和随机双盲安慰剂对照设计,定期基线评估持续2年。
- 结局指标包括计时25英尺步行、6分钟步行试验和12项MS步行量表。
主要发现
- 开放标签阶段步行速度改善11.5%,6分钟步行距离改善10.7%,MSWS-12改善6.1分。
- 双盲对照阶段步行速度改善13.1%,6分钟步行距离改善11.9%,MSWS-12改善7.4分。
- 长期治疗后超过10%或20%步行改善阈值的患者比例增加。
临床怎么用
- 法普鲁啶可作为步态受损多发性硬化患者的长期治疗选择。
- 临床中应定期重新评估药物疗效以优化治疗。
- 对初始药物反应不佳的患者,长期治疗后可能反应性增强,需特别关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To expand upon the limited knowledge of the long-term effects of prolonged-release (PR) fampridine in patients with multiple sclerosis (PwMS) regarding safety, walking improvements, and changes in drug responsiveness. METHODS: Fifty-three PwMS who completed the FAMPKIN core study were included in this extension trial. Drug efficacy was assessed in an open-label and randomized double-blind, placebo-controlled study design with regular baseline assessments over a period of 2 years using the Timed 25-Foot Walk (T25FW), 6-Minute Walk Test (6MWT), and 12-item MS Walking Scale (MSWS-12) as outcome measures. RESULTS: The data showed good tolerability and persisting efficacy of PR fampridine during long-term treatment in PwMS. Significant improvements in walking speed, endurance, and self-perceived ambulatory function were observed during open-label (T25FW: +11.5%; 6MWT: 10.7%; MSWS-12: 6.1 points) and double-blind controlled treatment with PR fampridine (T25FW: +13.1%; 6MWT: 11.9%; MSWS-12: 7.4 points). Several patients showed changes in drug responsiveness over time, resulting in an increased proportion of patients exceeding 10% or 20% improvements in walking measures after long-term treatment. CONCLUSIONS: Efficacy and tolerability data confirmed PR fampridine as a valuable long-term treatment for improving ambulatory function in gait-impaired PwMS. Similar results in open-label and double-blind phases reveal that the walking tests used are objective and reliable. The considerable proportion of patients in whom responsiveness to PR fampridine changed over time emphasizes the importance of regular reassessment of drug efficacy in clinical practice to optimize treatment. Such reassessments seem to be particularly important in patients with poor initial drug responses, as this group demonstrated enhanced responsiveness after long-term treatment. CLINICALTRIALSGOV IDENTIFIER: NCT01576354. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that PR fampridine significantly improved gait compared to placebo in a 2-week study in PwMS who had been using PR fampridine for 2 years.
引用
- Filli L, Zörner B, Kapitza S, et al. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. Neurology. 2017. PMID: 28148629. doi:10.1212/WNL.0000000000003656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。